Climb Bio, Inc. CLYM Common stock issuance for private placement
Common stock issuance for private placement at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfPrivatePlacement.
The official record: Climb Bio, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Climb Bio, Inc.'s common stock issuance for private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Climb Bio, Inc.'s common stock issuance for private placement?
- Climb Bio, Inc. (CLYM) reported common stock issuance for private placement of $0 in Q4 2025.
- How has Climb Bio, Inc.'s common stock issuance for private placement changed year-over-year?
- Climb Bio, Inc.'s common stock issuance for private placement decreased by 100.0% year-over-year, from $29.94M to $0.
- What does common stock issuance for private placement mean?
- Reflects the cash inflows generated from the sale of equity securities directly to private investors rather than through public markets. This is a primary mechanism for clinical-stage companies to secure funding for ongoing research and development activities.